Aeglea BioTherapeutics Investor Presentation Deck

Spyre is building a potentially best-in-class IBD pipeline with next-generation mAbs and rational combinations STRATEGY Potentially best-in-class mAbs Rational combinations TARGET a437 TL1A IL-23 Novel MOA a437 + IL-23 a437 + TL1A TL1A + IL-23 PROGRAM¹ SPY001 SPY002 SPY003 SPY004 SPY130 SPY120 SPY230 DISCOVERY IND-ENABLING CLINICAL Phase 1 interim data expected YE24 Phase 1 interim data expected 1H25 ¹Spyre exercised its option to license worldwide rights from Paragon Therapeutics, Inc. for SPY001. Spyre continues to hold an option to license similar rights from Paragon for all other programs. SPY003 license will be restricted to IBD, all other program licenses will be indication agnostic. SPYRE 7

View entire presentation